Healthy VolunteerPhase 1NCT07270783
Healthy Volunteer Study
A Phase 1 study testing D-2570 in people with Healthy Volunteer, run by InventisBio Co., Ltd at 1 site in United States.
Trial summary
Double Blinded Healthy Volunteer study evaluating D-2570 against placebo in various doses. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Volunteer
- What is being tested?
- D-2570
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 36 participants
- Where
- 1 siteUnited States
- Study dates
- 4 Dec 2025to Nov 2026
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy volunteer subjects meeting eligibility criteria
Who cannot join
- Subjects with ongoing or history of disease or co-morbidities as assessed by Principal Investigator which would make them ineligible for the study
- Subjects with a history of drug and alcohol abuse
- Subjects taking medications, over the counter or herbal remedies
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of D-2570 Tablets in Healthy Subjects
Double Blinded Healthy Volunteer study evaluating D-2570 against placebo in various doses.
Read the detailed description
Double blind study evaluating the safety, tolerability and PK data of D-2570/placebo in healthy volunteers.
- Conditions
- Healthy Volunteer
- Being tested
- D-2570, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
D-2570Drug
D-2570
PlaceboDrug
Placebo
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1 D-2570/Placebo | Experimental | Not described Receives: Drug: D-2570; Drug: Placebo |
| Cohort 2 D-2570/Placebo | Experimental | Not described Receives: Drug: D-2570; Drug: Placebo |
| Cohort 3 D-2570/Placebo | Experimental | Not described Receives: Drug: D-2570; Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of adverse events
Incidence of adverse events
Measured: From Informed Consent through study completion, an average of 48 days
Result of Pharmacokinetic endpoint
Tmax
Measured: From Randomization through study completion, an average of 20 days
Result of Pharmacokinetic endpoint
Cmax
Measured: From Randomization through study completion, an average of 20 days
Result of Pharmacokinetic endpoint
t1/2
Measured: From Randomization through study completion, an average of 20 days
Result of Pharmacokinetic endpoint
MRT
Measured: From Randomization through study completion, an average of 20 days
Result of Pharmacokinetic endpoint
AUC0-∞
Measured: From Randomization through study completion, an average of 20 days.
Result of Pharmacokinetic endpoint
AUC0-t
Measured: From Randomization through study completion, an average of 20 days
Result of Pharmacokinetic endpoint
CL/F
Measured: From Randomization through study completion, an average of 20 days
Result of Pharmacokinetic endpoint
Vz/F
Measured: From Randomization through study completion, an average of 20 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Dec 2025
- Study start4 Dec 2025
- Primary completion25 Jun 2026
- Study completionNov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy VolunteerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 36 participants (estimated)
Sponsor and investigators
- Lead sponsor
- InventisBio Co., Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07270783
- Sponsor's protocol ID
- D2570-103
- Status last verified
- Dec 2025
- First submitted
- 12 Nov 2025
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of D-2570 Tablets in Healthy Subjects
- ClinicalTrials.gov ID
- NCT07270783
- Acronym / sponsor ID
- D2570-103
- Conditions
- Healthy Volunteer
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 36 participants (estimated)
- Lead sponsor
- InventisBio Co., LtdIndustry (pharma, biotech, devices)
- Study start
- 4 Dec 2025 (actual)
- Primary completion
- 25 Jun 2026 (actual)
- Study completion
- Nov 2026 (estimated)
- First posted
- 8 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Double Blinded Healthy Volunteer study evaluating D-2570 against placebo in various doses.
Detailed description
Double blind study evaluating the safety, tolerability and PK data of D-2570/placebo in healthy volunteers.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Cohort 1 D-2570/Placebo | Experimental | Drug: D-2570, Drug: Placebo |
| Cohort 2 D-2570/Placebo | Experimental | Drug: D-2570, Drug: Placebo |
| Cohort 3 D-2570/Placebo | Experimental | Drug: D-2570, Drug: Placebo |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Healthy volunteer subjects meeting eligibility criteria
Key exclusion criteria (3 listed)
- Subjects with ongoing or history of disease or co-morbidities as assessed by Principal Investigator which would make them ineligible for the study
- Subjects with a history of drug and alcohol abuse
- Subjects taking medications, over the counter or herbal remedies
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| D-2570D-2570 | Drug | Cohort 1 D-2570/Placebo, Cohort 2 D-2570/Placebo, Cohort 3 D-2570/Placebo |
| PlaceboPlacebo | Drug | Cohort 1 D-2570/Placebo, Cohort 2 D-2570/Placebo, Cohort 3 D-2570/Placebo |
Primary outcome
Incidence of adverse events
Time frame: From Informed Consent through study completion, an average of 48 days
Incidence of adverse events
Result of Pharmacokinetic endpoint
Time frame: From Randomization through study completion, an average of 20 days
Tmax
Result of Pharmacokinetic endpoint
Time frame: From Randomization through study completion, an average of 20 days
Cmax
Result of Pharmacokinetic endpoint
Time frame: From Randomization through study completion, an average of 20 days
t1/2
Result of Pharmacokinetic endpoint
Time frame: From Randomization through study completion, an average of 20 days
MRT
Result of Pharmacokinetic endpoint
Time frame: From Randomization through study completion, an average of 20 days.
AUC0-∞
Result of Pharmacokinetic endpoint
Time frame: From Randomization through study completion, an average of 20 days
AUC0-t
Result of Pharmacokinetic endpoint
Time frame: From Randomization through study completion, an average of 20 days
CL/F
Result of Pharmacokinetic endpoint
Time frame: From Randomization through study completion, an average of 20 days
Vz/F
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Healthy Volunteer
Not yet recruitingObservational study
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
Blood Donors, Apheresis
Not yet recruitingPhase 1
Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast
Healthy Volunteers
Enrolling by invitationObservational study
Connors Protocol for the Management and Use of Stored Human Specimens (Stored Human Specimens)
Healthy Volunteer Samples
Not yet recruitingPhase 1
A Study of Safety of SUN-0864 and How it is Processed by and Affects the Body in Healthy Adults and Healthy Adults Who Are Overweight or Obese.
Healthy Participants
RecruitingObservational study
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
Eczema, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing D-2570 in people with Healthy Volunteer, run by InventisBio Co., Ltd at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of adverse events (time frame: From Informed Consent through study completion, an average of 48 days). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026.